ClinicalTrials.gg
RecruitingNCT05104112AUTMERUpdated Nov 9, 2026

Evaluation of a Therapeutic Education Program for Pregnant Women With a First Child Diagnosed With an Autism Spectrum Disorder

An interventional study of The M.E.R. program in Child Psychiatry, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 9, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris — 10 open to participants now, 11 under way, none of them phase 3. Autism Spectrum Disorder · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
Largest of 13
165 · median 27
Started
2025
with 1 other
No phase
9 of 17
5 open now
Primary completion
2029-03
later than 8 of 10 live
Registered
8th of 17
by date

Among the 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 8th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

10 of the 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Autism Spectrum Disorder (ASD) is a heterogeneous set of severe developmental abnormalities of the nervous system characterized by deficits affecting social interactions and verbal and non-verbal communication, as well as the presence of restricted interests, repetitive behaviors, and atypical sensory manifestations . ASD affects approximately 1% of the general population (Elsabbagh et al., 2012). Studies of siblings of individuals with ASD show that ASD is present in 7-20% of the offspring in families where a child has had a diagnosis of ASD and this prevalence increases if there are two diagnosed children.

Several studies show the benefits of interventions targeting parents\' interaction strategies in the early phases of development of infants at high risk for ASDs, in reducing the risk itself or its severity. Very early intervention, due to the presence of significant brain plasticity at these stages, may be particularly effective in changing these emerging trajectories, from a \"preventive intervention\" perspective that would aim to mitigate developmental risk and alter prodromal symptom trajectories, rather than eliminate a condition.

Our hypothesis is that the implementation of a specific therapeutic education program during a new pregnancy in the mother of a child with a diagnosis of ASD (MER Program) could improve the mother\'s well-being, increase parenting communication skills, and thereby improve interaction with the newborn at high risk for ASD. If the infant is affected, it may also reduce the symptoms of the disorder. Indirectly, it could also improve the well-being of the other parent involved in the interaction.

The M.E.R (Mères Ecoute Ressources) programme is a therapeutic education intervention aimed at mothers of children with ASD during a new pregnancy. This programme, which is being piloted in France and Europe, involves a number of dimensions, both educational and behavioural (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).

The programme comprises 8 one-to-one sessions lasting 1.5 hours every 15 days. The first and last of these are for assessment purposes, with the 6 intermediate sessions constituting the support. The structure of the programme and the sessions is based on what is recommended in therapeutic education. The sessions can take place on the hospital site or by teleconsultation (remote consultation used in the context of healthcare).

Read the detailed description

Randomized controlled trial with deferred start, French multicenter stepped-wedge type.

The start date of the intervention in each center will be done by randomization, defining 2 periods: a control period located before the start of the intervention, and an experimental period located after the start of the intervention.

This design allows the principal investigating team to train the centers associated in turn with the intervention, and to have a control group with structured follow-up but without intervention.

All subjects will be included before 26 ADT and assigned to the control or experimental group, depending on the time of inclusion and the randomization of the center to which they belong.

The follow-up will be conducted in 2 phases: 1. during pregnancy and 2. After the birth of the child.

Subjects included were pregnant women who already had a child with an ASD diagnosis, the second parent if present, and the newborn at risk for an ASD diagnosis.

The primary objective of this study is to evaluate the effect of an innovative therapeutic education program (the MER program) versus control in pregnant women with a first child followed for ASD on the quality of interaction strategies of the mother-infant dyad at 10 months postpartum.

The primary endpoint was the caregiver non-directiveness subscore of the Manchester Assessment of Caregiver-infant Interaction (MACI) scale at 10 months postpartum. This subscore is both the most sensitive to intervention and predictive of ASD diagnosis.

The first secondary objective is the evaluation of the effect of the MER versus control program on:

  • maternal pregnancy-related anxiety (PRAQ-R2 score) ;
  • Anxious and depressive symptomatology and quality of life (WhoQoL-Bref score) in the mother and the second parent during pregnancy (EPDS score) and up to 20 months of age of the newborn (HAM-Anxiety and HAM-Depression scores);
  • perceived stress related to pregnancy (ALES score)
  • mother-infant interaction at 10 and 20 months (MACI score and subscore);
  • autistic signs in at-risk infants at 20 months (ADOS Toddler score);

The second secondary objective was to study variables that could impact the effect of the intervention, including

  • adherence: compliance with sessions, satisfaction of participants (PEI-Parent score) ;
  • other variables that could modulate the effect of the intervention: sociodemographic variables (socioeconomic level, family configuration, number of children); clinical profile of the mother (intellectual efficiency (Raven\'s PM score), psychiatric comorbidities (DIGS, SRS score)); clinical profile of the child already diagnosed (ADI-R and ADOS score; developmental level); clinical profile of the infant at risk (gestational age, MSEL, IBQ-R and ECBQ scores).

The third secondary objective was to describe the barriers and levers to the implementation of the intervention.

Characteristics related to the implementation of the intervention (recruitment, uptake, fidelity, and implementation) will be collected, as well as the profile of mothers who did not participate in the project.

03

Conditions studied

  • Child Psychiatry

Keywords

  • autism spectrum disorder
  • therapeutic education
  • prevention
  • pregnancy
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mothers of children with a diagnosis of ASD, in pregnancy (before the 26th week of amenorrhea);
  • The diagnosis of ASD of the older child has been made, according to the DSM IV-TR or DSM 5 criteria, formalized by a diagnostic evaluation including if possible: the Autism Diagnostic Observation Schedule ADOS, and/or ADI
  • from mother and sec

Exclusion criteria

Exclusion Criteria:

  • Presence of a clearly identified and unstabilized severe psychiatric disorder in the mother (confirmed by medical interview and DIGS questionnaire conducted at the time of the inclusion visit) and/or intellectual disability;
  • Engagement in another form of individual therapeutic intervention.
  • Refusal of either parent (for child assessment, primary criterion)
  • Parents not proficient in French language
  • Persons (mother or second parent) under legal protection, guardianship or trusteeship, persons deprived of liberty, under court protection, under psychiatric care, under constraint, admitted to a health or social institution for purposes other than research
  • Persons with cognitive disorders or intellectual disabilities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
165 participants (estimated)

Study arms

  • No intervention
    control group

    Pregnant women followed by the center in the period before the intervention is implemented (the start of which is determined by randomization)

  • Experimental
    experimental group

    Pregnant women followed by the center during the period after the intervention is implemented (the start of which is determined by randomization)

    Other: The M.E.R. program

Interventions

  • OtherThe M.E.R. program

    The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother). It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or teleconsultation (remote consultation used in the context of healthcare).

06

What researchers measure

Primary outcomes

  1. Manchester Assessment of Caregiver-infant Interaction (MACI) "caregiver non-directiveness" subscore

    mother-baby interaction in the experimental group versus the control group at 5 months postpartum. This subscore is the most sensitive to intervention and predictive of ASD diagnosis.

    Time frame: 5 months after delivery

Secondary outcomes

  1. Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore

    To evaluate the effect of the MER program on maternal anxiety related to pregnancy

    Time frame: between 11 weeks and 26 weeks of gestation

  2. Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore

    To evaluate the effect of the MER program on maternal anxiety related to pregnancy

    Time frame: at 3 months after intervention

  3. Appraisal of Life Events Scale (ALES)

    Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale)

    Time frame: between 11 weeks and 26 weeks of gestation

  4. Appraisal of Life Events Scale (ALES)

    Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale

    Time frame: at 3 months after intervention

  5. Edimburgh Postnatal Depression Scale (EPDS)

    used to assess the risk of postnatal depression and is useful for identifying the presence of anxiety symptoms.The threshold retained for the French validation is 10.5, above which a depression is possible and below which the risk is very low.

    Time frame: 10 months after birth

  6. quality of life score-Bref (WhoQol-Bref)

    WHOQOL-BREF includes 26 items that measure the following broad domains: physical health, psychological health, social relationships and environment.

    Time frame: 10 months after birth

  7. parental anxiety score (HAM)

    hetero-questionnaire with 14 items, measuring both the psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) expression of anxiety. Each item is rated on a Likert scale from 0 to 4 (total range 0-56, where \<17= mild anxiety; 18-24= mild to moderate; 25-30 moderate to severe)

    Time frame: 10 months after birth

  8. mother's intelligence quotient

    measured by Raven's Progressive Matrices

    Time frame: between 11 weeks and 26 weeks of gestation

  9. Social Responsiveness Scale (SRS)

    to refine the evaluation of social difficulties in a dimensional way

    Time frame: between 11 weeks and 26 weeks of gestation

  10. Wechsler Mullen scale

    developmental level of the ASD child

    Time frame: between 11 weeks and 26 weeks of gestation

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2029, 46 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 46 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Nov 2024 → May 2025, primary completion Aug 2026 → Mar 2029 and completion Aug 2026 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Nov 2, 2021
StartActual
May 13, 2025was Nov 2024
Primary completionEst.
Mar 13, 2029was Aug 2026
CompletionEst.
Aug 13, 2029was Aug 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
Hôpital Robert Debré is now Recruiting
Nov 9, 2026
Start date
Nov 2024→May 13, 2025 (actual)
Nov 9, 2026
Primary completion
Aug 2026→Mar 13, 2029
Nov 9, 2026
Study completion
Aug 2026→Aug 13, 2029
Nov 9, 2026
Enrollment
132→165
Nov 9, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedThe diagnosis of ASD of the older child has been made, according to the DSM IV-TR or DSM 5 criteria, formalized by a diagnostic evaluation including if possible: the Autism Diagnostic Observation Schedule ADOS, the Autism Diagnostic Interview - Revised version (and/or ADI-R) accompanied by a cognitive evaluation of the child (Wechsler/Mullen Scales of Early Learning/Raven's Progressive Matrices);
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    Hôpital Robert Debré is now Recruiting
    Start date Nov 2024→May 13, 2025 (now actual)
    Primary completion Aug 2026→Mar 13, 2029
    Study completion Aug 2026→Aug 13, 2029
    Enrollment 132→165
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedThe diagnosis of ASD of the older child has been made, according to the DSM IV-TR or DSM 5 criteria, formalized by a diagnostic evaluation including if possible: the Autism Diagnostic Observation Schedule ADOS, the Autism Diagnostic Interview - Revised version (and/or ADI-R) accompanied by a cognitive evaluation of the child (Wechsler/Mullen Scales of Early Learning/Raven's Progressive Matrices);
    + 4 other changes: identifiers, verification date, oversight details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05104112
Responsible party
Sponsor
First posted
Nov 2, 2021
Start date
May 13, 2025
Primary completion
Mar 13, 2029 (estimated)
Completion
Aug 13, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Anita Beggiato, PHD
Contact
anita.beggiato@aphp.fr
0033140032000
Richard Delorme, PHD
Contact
richard.delorme@aphp.fr
0033140034130
Anita Beggiato, PHD
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion